Immunogenicity of Biopharmaceuticals: An Example from Erythropoietin - Protein structure, contaminants, formulation, container, and closure all can affect the immunogenicity of the product. - BioPharm

ADVERTISEMENT

Immunogenicity of Biopharmaceuticals: An Example from Erythropoietin
Protein structure, contaminants, formulation, container, and closure all can affect the immunogenicity of the product.


BioPharm International
Volume 18, Issue 8


Marc H. V. van Regenmortel, Ph.D
Biotechnology-derived therapeutic proteins are playing an ever-increasing role in the pharmaceutical market. These proteins are mostly used in the treatment of life-threatening and severe diseases. The aim is to correct an acquired or inherited deficiency of a native protein or to alter a disease process. Interestingly, most therapeutic proteins have been shown to be immunogenic, despite the fact that the amino acid sequence is identical or nearly identical to endogenous proteins. The formation of antibodies appears, in many cases, not to have a clinical effect.

There are cases, however, in which antibodies were found to be neutralizing, which can negate the effect of the therapy or when cross-reacting with the endogenous protein, deplete the effect of this protein. The clinical effects of such cases are significant, and can result in a more severe disease and a need for acute intervention. Several potential mechanisms can cause immunogenicity of therapeutic proteins such as aggregates, molecular mimicry, adjuvants, neo-antigens, and modification of the protein. Epoetin is an example of one display of this mechanism.

THERAPEUTIC PROTEINS




Over the past 20 years our understanding of immunology has grown exponentially, and there is no end in sight. Because of the complexity of this field, any discussion related to the formation of antibodies requires simplification since there are multiple potential routes for the production of antibodies against a therapeutic protein. In general, we focus on the most common pathways. For a more detailed discussion, the book by Abbas and Lichtman serves as a good reference.1

The number of biotechnology-derived therapeutic proteins now available includes over 75 products representing 65 different types of molecules.2 In spite of the fact that biopharmaceuticals currently have only a small share of the pharmaceutical market, their medical impact is enormous. Examples of deficiency correction are recombinant human-insulin therapy for diabetes mellitus, therapy with factor VIII in patients with hemophilia A, and recombinant human erythropoietin (epoetin) therapy for the treatment of anemia. An example of a biopharmaceutical that alters disease processes is the use of recombinant interferons in patients with multiple sclerosis, hepatitis, and cancer.


Figure 1. Development of Central and Peripheral Tolerance to Self Antigens
The majority of therapeutic proteins have an identical or nearly identical amino acid sequence of endogenous proteins, and may not be immunogenic if they are recognized as self through mechanisms of immune tolerance (Figure 1). Yet, nearly all of the biopharmaceuticals currently approved for clinical use are known to be immunogenic.3 Subtle differences in protein structure, a lack of tolerance in the patient, or the presence of an adjuvant may result in the generation of an antibody response. In many cases of antibody formation to biopharmaceuticals, there is no clinical effect.3-5

In some cases antibodies may be neutralizing, which can negate the effect of the therapy.6-16 Cross-reaction with the endogenous protein can deplete the effect of this protein.17-19 This effect has been observed in the management of anemia in chronic kidney disease patients, where cross-reactive neutralizing antibodies were found to inhibit the activity of both the administered epoetin and the patient's own residual erythropoietin.18,19 This created a more severe anemia, called pure red-cell aplasia (PRCA), characterized by an almost complete absence of red-blood-cell precursors in bone marrow.18,19 In the majority of reported cases of PRCA, the presence of anti-erythropoietin antibodies has been confirmed, resulting in the condition named antibody-mediated PRCA (Ab+PRCA).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines
Source: BioPharm International,
Click here